VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. AGN Neuro is the world’s first company to investigate DMT for the tre
Algernon Pharmaceuticals Inc says unit initiates traumatic brain injury research program with DMT; appoints global TBI expert as advisor proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in.
Izzy Blay was diagnosed at eight-months-old with a form of cerebral palsy called right sided hemiplegia, which affects muscle movement. As a result, she experie